Home » Topics » Regulatory » EMA

EMA
RSS

EMA committee recommends approval of Trelegy Ellipta for COPD

Sep. 15, 2017

EMA grants orphan drug designation to seladelpar for primary biliary cholangitis

Sep. 12, 2017

EMA grants orphan drug designation to Vivus' tacrolimus for PAH

Sep. 7, 2017

FDA, EMA grant orphan drug designation to QRX-421 for Usher syndrome

Sep. 6, 2017

EMA validates for review MAAs for combination of binimetinib and encorafenib

Aug. 28, 2017

Tetraphase Pharmaceuticals submits marketing application for i.v. eravacycline in Europe

Aug. 18, 2017

EMA announces business continuity plan to prepare for U.K.'s withdrawal from the E.U.

Aug. 4, 2017

EMA's CHMP recommends Verkazia for severe vernal keratoconjunctivitis in children and adolescents

July 25, 2017

EMA committee recommends approval of Vimpat for focal-onset seizures in children

July 25, 2017

EMA committee recommends against approval of Onzeald

July 25, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...